Witsch-Baumgartner M, Löffler J, Utermann G
Institute of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria.
Hum Mutat. 2001 Mar;17(3):172-82. doi: 10.1002/humu.2.
The Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder characterized by variable congenital malformations, facial dysmorphism, and mental retardation. Mutations in the DHCR7 gene have been identified in SLOS patients. This gene encodes for the enzyme Delta7-sterol reductase which catalyses the last step of cholesterol biosynthesis. Among the 73 different mutations observed so far, including 10 novel mutations reported in this review, the majority are missense mutations (65) which cluster in three domains of the protein: in the transmembrane domain (TM mutations), in the fourth cytoplasmic loop (4L mutations), and at the C-terminus (CT mutations). Two nonsense mutations, one splice site mutation, two single nucleotide insertions, and three deletions which likely all represent null mutations were also described. Expression studies have demonstrated a decreased protein stability for all analyzed missense mutations. By comparing clinical severity scores, biochemical data, and mutations in SLOS patients a genotype-phenotype correlation has been established. The null and 4L mutations are associated with a severe clinical phenotype, and TM and CT mutations are associated with a mild clinical phenotype. DHCR7 mutational spectra in SLOS patients of British, German, Italian, and Polish origin demonstrate significant geographic frequency differences of common DHCR7 mutations.
史密斯-勒米-奥皮茨综合征(SLOS)是一种常染色体隐性代谢紊乱疾病,其特征为先天性畸形、面部畸形和智力发育迟缓。已在SLOS患者中发现DHCR7基因突变。该基因编码δ7-甾醇还原酶,此酶催化胆固醇生物合成的最后一步。在迄今观察到的73种不同突变中,包括本综述报道的10种新突变,大多数为错义突变(65种),这些突变集中在蛋白质的三个结构域:跨膜结构域(TM突变)、第四胞质环(4L突变)和C末端(CT突变)。还描述了两个无义突变、一个剪接位点突变、两个单核苷酸插入和三个缺失,这些可能都代表无效突变。表达研究表明,所有分析的错义突变的蛋白质稳定性均降低。通过比较SLOS患者的临床严重程度评分、生化数据和突变情况,已建立了基因型-表型相关性。无效突变和4L突变与严重临床表型相关,TM和CT突变与轻度临床表型相关。英国、德国、意大利和波兰血统的SLOS患者的DHCR7突变谱显示,常见DHCR7突变存在显著的地理频率差异。